{"id":"W2947482799","doi":"10.1200/jco.2019.37.15_suppl.9014","title":"A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Internal medicine; Clinical endpoint; Lung cancer; Gastroenterology; Interim analysis; Response Evaluation Criteria in Solid Tumors; Biomarker; Phases of clinical research; Progression-free survival; Stage (stratigraphy); Oncology; Randomized controlled trial; Cancer; Immunotherapy; Clinical trial; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002689259,0.002065539,0.002409212,0.0004778921,0.0004209543,0.001089723,0.001264609,0.001382177,0.007915271],"category_scores_gemma":[0.001723026,0.0009302523,0.001610321,0.0004174548,0.001216102,0.001034087,0.0005875718,0.003554248,0.001544047],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001435987,"about_ca_system_score_gemma":0.002325121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001194091,"about_ca_topic_score_gemma":0.003919655,"domain_scores_codex":[0.9993333,0.0003659142,0.00002902896,0.0001121953,0.00004689532,0.0001125801],"domain_scores_gemma":[0.9989756,0.0001947874,0.0002201993,0.00007151485,0.00005583846,0.0004820492],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9652206,0.01613334,0.0009263585,0.0002976121,0.0005993845,0.00003143747,0.00005896905,0.0004126693,0.003048983,0.0001172689,0.001376325,0.01177703],"study_design_scores_gemma":[0.9057387,0.09096491,0.001629158,0.00001534378,0.0002305968,0.0000245387,0.00001911484,0.0004100901,0.0002554325,0.0001418167,0.0005611574,0.000009142463],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800729,0.002048536,0.0007999292,0.0007864087,0.0006433582,0.01064808,0.001768223,0.0001441956,0.003088387],"genre_scores_gemma":[0.9771923,0.001257393,0.002071501,0.001816821,0.0004585728,0.01016244,0.002149571,0.00003660482,0.004854702],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007915271,"threshold_uncertainty_score":0.02647918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03816719068031371,"score_gpt":0.4079229977577635,"score_spread":0.3697558070774498,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}